RaQualia Pharma
4579.TTSE GROWTHPharmaceutical
Financials · Standalone
| Fiscal year ended | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|---|
| Operating income | ¥691m | ¥323m | −¥478m | ¥683m | ¥505m | — |
| Ordinary income | ¥662m | ¥197m | −¥445m | ¥701m | ¥656m | −¥550m |
| Total assets | ¥11.0bn | ¥9.7bn | ¥6.6bn | ¥6.1bn | ¥5.2bn | ¥4.4bn |
| Net assets / equity | ¥7.4bn | ¥5.9bn | ¥5.9bn | ¥5.3bn | ¥4.8bn | ¥4.1bn |
| EPS (basic) | ¥21.06 | ¥2.6 | ¥-19.95 | ¥27.83 | ¥29.34 | ¥-31.26 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 16
| Period | Form | Figures |
|---|---|---|
| 2026-01-01 → 2026-06-30 | Half-year | 63 figures · EDINET |
| 2025-01-01 → 2025-12-31 | Annual | 181 figures · EDINET |
| 2025-01-01 → 2025-06-30 | Half-year | 62 figures · EDINET |
| 2024-01-01 → 2024-12-31 | AnnualAmended | 177 figures · EDINET |
| 2024-01-01 → 2024-12-31 | Annual | 177 figures · EDINET |
| 2024-01-01 → 2024-06-30 | Half-year | 63 figures · EDINET |
| 2023-01-01 → 2023-12-31 | AnnualAmended | 179 figures · EDINET |
| 2024-01-01 → 2024-03-31 | Quarterly Q1 | 62 figures · EDINET |
| 2023-01-01 → 2023-12-31 | Annual | 179 figures · EDINET |
| 2023-01-01 → 2023-09-30 | Quarterly Q3 | 66 figures · EDINET |
| 2023-01-01 → 2023-03-31 | Quarterly Q1Amended | 63 figures · EDINET |
| 2023-01-01 → 2023-06-30 | Quarterly Q2 | 67 figures · EDINET |
| 2023-01-01 → 2023-03-31 | Quarterly Q1 | 63 figures · EDINET |
| 2022-01-01 → 2022-12-31 | Annual | 179 figures · EDINET |
| 2022-01-01 → 2022-09-30 | Quarterly Q3 | 67 figures · EDINET |
| 2022-01-01 → 2022-06-30 | Quarterly Q2 | 67 figures · EDINET |
24 more reports are still being processed.